|
|
|
|
Carbaglu Approved for Rare Genetic Disorder
THURSDAY, March 18 (HealthDay News) -- The drug Carbaglu (carglumic acid) has been approved by the U.S.Food and Drug Administration to treat a rare genetic disorder called N-acetylglutamate synthase (NAGS deficiency), which results in elevated blood levels...
|
|
|
Complications Relatively Common With Neonatal CPAP
THURSDAY, March 18 (HealthDay News) -- For patients in the neonatal intensive care unit (NICU), complications are relatively frequent with continuous positive airway pressure (CPAP), but not with cannula supplementation, according to a study in the March issue...
|
|
|
Cpex reports preliminary results from clinical study of nasal insulin product
(Datamonitor via COMTEX) Cpex Pharmaceuticals, a specialty pharmaceutical company, has reported preliminary results related to its Phase IIa proof-of-concept clinical trial of the company's nasal insulin product, Nasulin.According to the company, the...
|
|
|
Effects of Nasal Continuous Positive Airway Pressure and Cannula Use in the Neonatal Intensive Care Unit Setting
Jatana KR et al.Effects of Nasal Continuous Positive Airway Pressure and Cannula Use in the Neonatal Intensive Care Unit Setting.
|
|
|
Rescue Workers Can Prevent Brain Damage With Icy Nasal Spray
ePublishing :: CMS, Hosting & Web Development | Copyright by FDAnews All right Rescue Workers Can Prevent Brain Damage With Icy Nasal Spray.
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results From Its Phase 2a Clinical Trial Of Nasulin
CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin. The study was designed to evaluate the efficacy and safety of Nasulin versus...
|
|
|
News and FDA Updates for Gilead (Nasdaq:GILD), CPEX (NASDAQ:CPEX), Green Star (OTC:GSPI)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Medical News: CPEX Pharmaceuticals Announces Preliminary Results From Its Phase 2a Clinical Trial Of Nasulin
CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin. Medical News: CPEX Pharmaceuticals Announces Preliminary Results From Its...
|
|
|
Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
MISSISSAUGA, ON The randomized, double-blind, placebo-controlled, single-centre trial will assess the efficacy and safety of WF10 infusions for the treatment of patients with severe persistent allergic rhinitis.The trial will enroll 50 patients who have at...
|
|
|
Study Assesses Complications Associated With Nasal Ventilation In Newborns
More than 10 percent of newborns who receive oxygenation and ventilation using nasal continuous airway pressure in the neonatal intensive care unit (NICU) may experience complications inside or outside the nose, according to a report in the March issue of...
|
|
|
Rescue Workers Can Prevent Brain Damage with Icy Nasal Spray
After cardiac arrest, lowering someones body temperature can prevent life-threatening brain damage.Its so critical that New York City requires ambulances to take some patients up to 20 minutes out of the way to hospitals with cooling equipment. EMTs could...
|
|
|
Common Cold Symptoms Not Washed Away by Nose Irrigation
Washing out your nose with a spray or spout of salt water is safe and might even get you back to work sooner after a cold or acute sinus infection.However, there is not enough evidence to show that it can reduce your symptoms significantly, according to a...
|
|
|
NUVO RESEARCH ENROLLS FIRST PATIENT IN PHASE 2 WF10 ALLERGIC RHINITIS TRIAL
Nuvo Research announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis Mississauga, Ontario, Canada | March 15, 2010 | Nuvo Research Inc.(TSX: NRI), a Canadian drug...
|
|
|
Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ - Nuvo Research Inc.(TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug...
|
|
|
kDNA minicircle signatures of Leishmania (Viannia) braziliensis in oral and nasal mucosa from mucosal leishman
Fernanda Santos de Oliveiraa, , , Cludia Maria Valete-Rosalinob, c, Armando de Oliveira Schubachb and Raquel da Silva Pachecoa a Laboratrio de Sistemtica Bioqumica, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ CEP 21045-900, Brazil b Laboratrio de...
|
|
|
Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ -- Nuvo Research Inc.(TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug...
|
|
|
Universal Detection Technology Addresses First Responder Anthrax Vaccinations
Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, issued a response today to a growing interest in...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin?
EXETER, N.H.(BUSINESS WIRE) CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin?.The study was designed to evaluate the...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin News source: Business Wire CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of...
|
|
|
CPEX Pharma (CPEX) Updates on Nasulin Phase 2a
CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Companys nasal insulin product, Nasulin. The study was designed to evaluate the efficacy and safety of Nasulin...
|
|
|
Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin
CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Companys nasal insulin product, Nasulin. The study was designed to evaluate the efficacy and safety of Nasulin...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin
EXETER, N.H.- (BUSINESS WIRE) - CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin. The study was designed to evaluate...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin?
3/17/10 - CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin?EXETER, N.H.(BUSINESS WIRE) CPEX Pharmaceuticals Inc? (NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin
EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals Inc.(NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company?s nasal insulin product, Nasulin?. The study was designed to evaluate the...
|
|
|
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin
Companies mentioned in this article: CPEX Pharmaceuticals Inc.EXETER, N.H. -- (BUSINESS WIRE) -- CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Companys nasal...
|
